TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01773408
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m\^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m\^2 IV infusion daily.
Study: NCT03657550
Drug: Levamlodipine, Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
Study: NCT00917449
Drug: L-arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine (3.2 gr bid)for 18 months
Study: NCT00077857
Drug: docetaxel (Taxotere®)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 intravenous on day 1 of each 3 week cycle
Study: NCT02105454
Drug: Grazoprevir (GZR)
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg oral tablet (total daily dose)
Study: NCT02105454
Drug: Elbasvir (EBR)
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg oral capsule (total daily dose = 5 capsules)
Study: NCT02105454
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg oral capsule (total daily dose = 4-7 capsules)
Study: NCT00326898
Drug: Sorafenib Tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00326898
Drug: Sunitinib Malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01667471
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg iv every 4 weeks, 104 weeks
Study: NCT02503904
Drug: cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)
Normalized name: metronidazole and diloxanide
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02953535
Drug: Sovaldi (fist dose)
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet contains 400 mg sofosbuvir
Study: NCT02953535
Drug: Sovaldi (second dose)
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet contains 400 mg sofosbuvir
Study: NCT00493870
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
Study: NCT02834637
Drug: bivalent HPV vaccine
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: head to head comparisons of different dose schedules and HPV vaccine types
Study: NCT03657550
Drug: Amlodipine, Levamlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
Study: NCT02834637
Drug: nonavalent HPV vaccine
Normalized name: HPV-16 trojan peptide vaccine
DrugBank: HPV-16 trojan peptide vaccine (DB17496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: head to head comparisons of different dose schedules and HPV vaccine types
Study: NCT01002378
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of regorafenib will be administered immediately following a high fat breakfast
Study: NCT01002378
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of regorafenib will be administered immediately following a low fat breakfast
Study: NCT01002378
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of regorafenib will be administered following an overnight fast
Study: NCT01002807
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 10 mg, Single Dose
Study: NCT01002807
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 1000 mg, Single Dose
Study: NCT01002807
Drug: Glucophage
Normalized name: Glucophage
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 1000 mg, Single Dose
Study: NCT00703638
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administered intravenously, 75 mg/m\^2 over 1-2 hours on day 1 of a 21 day cycle
Study: NCT00703638
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m\^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle
Study: NCT00703638
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily oral sorafenib (200 mg or 400 mg bid)
Study: NCT03189446
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
Study: NCT03189446
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
Study: NCT04374864
Drug: Trelagliptin
Normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Anti diabetic
Study: NCT00883337
Drug: Interferon β-1a
Normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sterile preservative-free solution packaged in graduated pre-filled syringes~Subcutaneous injection~Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®
Study: NCT00883337
Drug: Teriflunomide
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Film-coated tablet~Oral administration
Study: NCT00527605
Drug: Dutasteride 0.5mg capsule
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride 0.5mg once daily orally
Study: NCT00527605
Drug: Dutasteride matched placebo
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride matched placebo once daily orally
Study: NCT02695472
Drug: 80 Milligrams NSI-189
Normalized name: ethanol
DrugBank: NSI-189 (DB16230)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally Administered
Study: NCT02695472
Drug: 40 Milligrams NSI-189
Normalized name: ethanol
DrugBank: NSI-189 (DB16230)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally Administered
Study: NCT00763139
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg by mouth once a day for 8 weeks
Study: NCT01951469
Drug: Gefitinib and Pemetrexed/platinum
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) or Pemetrexed (D1) + nedaplatin (D1) chemotherapy, every 28 days
Study: NCT01951469
Drug: Gefitinib mono-therapy
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib 250mg is Taken Orally everyday
Study: NCT04312009
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan; 50 mg daily; oral administration
Study: NCT01256437
Drug: Aqua cream
Normalized name: ALLANTOIN 1 g in 100 g TOPICAL LIQUID [Mineral Aqua Cream]
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ointment once daily for 1 month
Study: NCT04624360
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous of Dexamethasone 8 mg post clamping of the umbilical cord
Study: NCT01146678
Drug: Insulin glargine HOE901
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study: NCT01146678
Drug: Lixisenatide AVE0010
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study: NCT02055716
Drug: alpha-cyclodextrin
Normalized name: alpha-cyclodextrin
DrugBank: Alpha-Cyclodextrin (Cyclohexa-Amylose) (DB01909)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00542555
Drug: Naproxcinod 375 mg
DrugBank: Naproxcinod (DB06682)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00542555
Drug: Naproxcinod 750 mg
DrugBank: Naproxcinod (DB06682)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03899428
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500 mg IV (intravenous infusion)
Study: NCT03899428
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescribed by physician.
Study: NCT03899428
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prescribed by physician.
Study: NCT03899428
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prescribed by physician.
Study: NCT03899428
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prescribed by physician.
Study: NCT00223496
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
Study: NCT02200380
Drug: CDX-301
Normalized name: CDX-301
DrugBank: CDX-301 (DB19293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Related donors will receive CDX-301 for 5 days or 7 days.
Study: NCT02200380
Drug: CDX-301 and plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
Study: NCT02889796
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 200 mg or 100 mg tablet(s) administered orally once daily
Study: NCT02889796
Drug: Placebo to match filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Tablet(s) administered orally once daily
Study: NCT02889796
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40 mg administered via subcutaneous injection once every two weeks
Study: NCT02889796
Drug: Placebo to match adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered via subcutaneous injection once every two weeks
Study: NCT02889796
Drug: MTX
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercially sourced tablet(s) administered orally
Study: NCT00787891
Drug: rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
Study: NCT00787891
Drug: rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
Study: NCT00739674
Drug: losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])
Normalized name: hydrochlorothiazide / losartan potassium Pill
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:~Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:~* Losartan 50 mg~* Losartan 100 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~Patients with severe hypertension:~* Losartan 50 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~* Losartan 100 mg/HCTZ 25 mg + increasing CCB
Study: NCT00254904
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
Study: NCT00933049
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amoxicillin (25mg/kg/dose)for 5 days
Study: NCT00933049
Drug: Cotrimoxazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole)
Study: NCT00933049
Drug: Amoxicillin placebo
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00999414
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.~Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.~For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2.
Study: NCT04970251
Drug: Aflibercept Ophthalmic
Normalized name: aflibercept ophthalmic
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.
Study: NCT00254904
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
Study: NCT00254904
Drug: PF-3512676
Normalized name: PF-3512676 free acid
DrugBank: Agatolimod (DB15018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity
Study: NCT00254904
Drug: Gemcitabine + Cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
Study: NCT01068132
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,
Study: NCT01888458
Drug: Micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients meeting selection criteria will receive micafungin IV. Prophylaxis will start within 48 hours of the beginning of the transplant-related conditioning regimen until 5 days after recovery from neutropenia (ANC ≥ 500/µl), or occurrence of an IFI, or up to 42 days, or withdrawal for any reason (e.g. patient's or investigator's decision, development of intolerance, death), whichever come first
Study: NCT00267748
Drug: Sunitinib Malate Continuous Daily Dosing
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
Study: NCT00267748
Drug: Sunitinib Malate Schedule 4/2
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
Study: NCT03245450
Drug: Eribulin mesilate
Normalized name: Eribulin mesilate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT03245450
Drug: Irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT00907400
Drug: PN400
Normalized name: Pantoprazole sodium
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT00705939
Drug: Taliglucerase alfa
Normalized name: Taliglucerase alfa
DrugBank: Taliglucerase alfa (DB08876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion every 2 weeks
Study: NCT02849132
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral entecavir 0.5mg daily for 8 years
Study: NCT02776163
Drug: Nedaplatin
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nedaplatin 35mg/m\^2，D1-2，2 cycles
Study: NCT02776163
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 70mg/m\^2，D1，2 cycles
Study: NCT00488384
Drug: Chemopreventive application (Acitretin)
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemopreventive application (Acitretin)
Study: NCT02007174
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02007174
Drug: Medical Treatment
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
Study: NCT00104897
Drug: tanespimycin
Normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01558661
Drug: AG-013736 (AXITINIB)
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All eligible patients will receive a starting axitinib dose of 5 mg twice daily (BID) taken orally in 4-week (28-day) cycles. Patients who tolerate axitinib with no adverse events related to study drug above CTCAE v. 4.0 Grade 2 for a consecutive 2-week period may have their dose increased by one dose level according to the discretion of the treating physician (NOT allowed for patients with blood pressure (BP) \> 150/90 mm Hg or who are receiving antihypertensive medication). This dose escalation is not mandatory. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity.
Study: NCT00282503
Drug: Methoxsalen+ECP, Methylprednisolone
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~* Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~* Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be \> 4 days between the ECP treatments within a week.)~Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:~Daily Dose (mg/kg)~1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10
Study: NCT02449655
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
Study: NCT02906618
Drug: 3C 15N 2H-LY3039478 IV
Normalized name: sodium nitrate 15N
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02364479
Drug: 50mg Yisaipu
Normalized name: Yisaipu
DrugBank: Yisaipu (DB17076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
Study: NCT02364479
Drug: 25mg etanercept
Normalized name: etanercept 25 MG/ML
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
Study: NCT01926782
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Study: NCT04344678
Drug: Sildenafil Citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esitalopram 20 mg tablet plus Sildenafil Citrate 50 mg tablet once daily
Study: NCT00271323
Drug: docetaxel and cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
Study: NCT00453271
Drug: NB-002
Normalized name: Nb
DrugBank: Niobium (DB13031)
Approvals — FDA: no, EMA: no, PMDA: no